Skip to main content

Table 2 In a multivariate analysis of breast cancer cases, the expression of YB-1 was better than HER-2 or ER in predicting reduced BCSS

From: Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes

Prognostic marker

Patients with reduced BCSS

 

HR (95% CI)

P value

Nodal status

  

   Positive versus negative

2.405 (2.083 to 2.776)

4.6 × 10-33

Tumor size (cm)

  

   2 to 5

1.605 (1.387 to 1.859)

2.8 × 10-10

   >5

2.269 (1.749 to 2.943)

2.8 × 10-10

Grade

  

   III versus II versus I

1.416 (1.215 to 1.651)

8.9 × 10-6

Age (years)

  

   <50 versus = 50

1.160 (1.000 to 1.345)

5.0 × 10-2

ER

  

   Positive versus negative

0.816 (0.720 to 0.991)

3.8 × 10-2

Her-2

  

   Positive versus negative

1.259 (1.052 to 1.506)

1.2 × 10-2

YB-1

  

   Positive versus negative

1.456 (1.257 to 1.656)

5.6 × 10-7

  1. YB-1 was approximately equal to the power of tumor grade yet not as accurate as tumor size or nodal status in predicting reduced BCSS. BCSS, breast cancer specific survival; CI, confidence interval; ER, estrogen receptor; HER, human epidermal growth factor receptor; HR, hazard ratio; YB-1 = Y-box binding protein-1.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us